Absci (NASDAQ:ABSI – Get Free Report) and Geron (NASDAQ:GERN – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation and risk.
Risk and Volatility
Absci has a beta of 2.27, meaning that its share price is 127% more volatile than the S&P 500. Comparatively, Geron has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500.
Profitability
This table compares Absci and Geron’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Absci | -7,756.38% | -61.71% | -54.52% |
| Geron | -34.17% | -24.48% | -10.30% |
Institutional & Insider Ownership
52.0% of Absci shares are held by institutional investors. Comparatively, 73.7% of Geron shares are held by institutional investors. 10.5% of Absci shares are held by insiders. Comparatively, 1.7% of Geron shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares Absci and Geron”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Absci | $1.56 million | 1,030.12 | -$115.18 million | ($0.80) | -11.71 |
| Geron | $204.56 million | 3.55 | -$83.50 million | ($0.11) | -10.27 |
Geron has higher revenue and earnings than Absci. Absci is trading at a lower price-to-earnings ratio than Geron, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent ratings and price targets for Absci and Geron, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Absci | 1 | 0 | 10 | 0 | 2.82 |
| Geron | 1 | 2 | 2 | 0 | 2.20 |
Absci presently has a consensus target price of $14.56, indicating a potential upside of 55.34%. Geron has a consensus target price of $4.00, indicating a potential upside of 253.98%. Given Geron’s higher probable upside, analysts plainly believe Geron is more favorable than Absci.
Summary
Geron beats Absci on 9 of the 14 factors compared between the two stocks.
About Absci
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.
About Geron
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Receive News & Ratings for Absci Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Absci and related companies with MarketBeat.com's FREE daily email newsletter.
